News
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
9h
Health on MSNWeight Loss Drugs Like Ozempic May Also Protect Against Dementia, Stroke, and Even DeathGLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...
Tom Nolan reviews this week’s research Cannabinol—aka CBD—is a modern day tonic for almost any ailment, available in all good vape shops and petrol stations. In 2023, the Food Standards Agency cut the ...
Wellbeing Whisper on MSN16h
Why Does Weight Come Back After Stopping Weight Loss Drugs? Here’s What Actually HelpsCan it really be maintained after they’re discontinued on top-selling drugs such as Ozempic or Wegovy, or is rebound weight gain simply a natural part of the process? For many adult patients taking ...
14h
GlobalData on MSNApnimed sets sights on sleep apnoea pill approval following Phase III winPositive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.
GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...
Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.
Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results